ISPOR - High-cost biologics for rheumatoid arthritis- how are payer-led cost-taming strategies impacting brand uptake in the united states?

Full Text

High-cost biologics for rheumatoid arthritis- how are payer-led cost-taming strategies impacting brand uptake in the united states?

Abstract

Authors

J. Cox C. Lewis R. Moore

Back to Volume 18, Issue 3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now